Management

Born: 1962

Mr. Øvlesen is an experienced biotech executive and has been involved as founder/CEO/Chairman/board member in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Perfusion Tech, Resother Pharma, Cercare Medical, PNN Medical, Cereno Scientific and TXP Pharma. Mr. Øvlesen was CEO of Synact Pharma from 2015-2023 taking the company public at Spotlight and later at Nasdaq (Stockholm). Mr. Øvlesen holds an MBA from University of Hartford, United States.

Independent in relation to the company and the company management: No

Independent in relation to the major shareholders: Yes

Holdings: Jeppe Øvlesen owns 50% of Quantass ApS and 26.67% of the shares in GoodWind Holding GmbH that both holds shares directly in SynAct Pharma. See this page for updated holdings

Björn Westberg has more than 25 years of experience in the life science sector and has served as a chief financial officer since 2001.

Prior to joining SynAct Pharma in June 2023, he was CFO at privately held Attgeno. Before that he was CFO at global cloud software company Enea, Swedish medtech Bonesupport, both of which are listed on Nasdaq Stockholm, and pharmaceutical developer and manufacturer Recipharm. He started his career at AstraZeneca where he worked in various capacities from 1989-2001.

Holdings: See this page for updated holdings

Thomas Boesen, PhD, has more than 20 years of experience in the biotech and pharma industry. He holds a PhD in bioorganic chemistry from Copenhagen University, with studies at Cambridge University, and a MA in technology management with studies at Roskilde and Edinburgh Universities.

Dr Boesen’s achievements include being an inventor on 35 granted patents and holding several managing positions. Dr. Boesen has been a part of the successes of Action Pharma and Epitherapeutics, and he was cofounder of MedChem and TXP Pharma. He brings insight in drug development throughout the clinical phases, with a focus on CMC and external collaboration. Prior to joining SynAct Pharma, Dr Boesen was with Novo Nordisk for 5 years.

Holdings: Dr. Boesen holds 18.67% of the shares in GoodWind Holding GmbH. GoodWind Holding GmbH holds shares in SynAct Pharma AB. See this page for updated holdings

Kirsten Harting, MD and Executive MBA has more than 30 years of experience in the established pharma industry and biotech and is the Chief medical Officer at Synact Pharma. She is a Medical Doctor from Copenhagen University and has an Executive MBA from Copenhagen Business School (former SIMI). She has in-depth knowledge about development with comprehensive early and late clinical phase experience, including the approval of new medicines.

She has had the responsibility for development and approval of several drugs reaching the market. Beside the medical and scientific knowledge, Kirsten has commercial and business understanding, which she integrates into the development of new medicine increasing the likelihood of commercial success as well as improving the lives of patients.

Holdings: See this page for updated holdings

Thomas Jonassen, MD, is associate professor at cardiovascular pharmacology, University of Copenhagen, and visiting professor at William Harvey Research Institute, Barts and London School of Medicine. He has published more than 50 scientific publications and is the inventor of 6 granted patents in the US and Europe.

Dr. Jonassen is cofounder and current CSO and BoD member at SynAct Pharma AB, cofounder of ResoTher Pharma Aps, cofounder and former CSO at Action Pharma A/S, and cofounder of TXP Pharma AG. Action Pharma sold its lead drug development candidate to AbbVie for $110M USD and TXP Pharma sold various rights to Questcor Pharmaceuticals for $100M USD in milestone payments. Dr. Jonassen is coinventor of SynAct’s drug candidate, AP1189.

Holdings: Dr. Jonassen holds 100% of the shares in TJ Biotech Holding ApS. TJ Biotech Holding ApS holds 26.67% of the shares in GoodWind Holding GmbH. TJ Biotech Holding ApS, and GoodWind Holding GmbH hold shares in SynAct Pharma AB.  See this page for updated holdings

James Knight has 25 years of experience in biotech. Previously he was the VP of Portfolio Strategy at Questcor Pharmaceuticals where he was responsible for leading the expansion of Acthar Gel from two to nine promoted indications across five specialty areas including rheumatology. Questcor’s success in expanding Acthar use lead to its acquisition by Mallinckrodt for $5.6 billion.

After his time at Questcor Mr. Knight previously also served as the CBO of TXP Pharma and the SVP, Head of Corporate Development for BioTime. Prior to Questcor, Jim Knight held positions of increasing responsibility at Elan Pharmaceuticals, Dura Pharmaceuticals and Biogen. Jim has a Bachelor of Science in Biology from the University of Massachusetts, Amherst, and a Master of Business Administration in High Technology from Northeastern University in Boston.

Holdings: See this page for updated holdings